Compile Data Set for Download or QSAR
Report error Found 82 Enz. Inhib. hit(s) with all data for entry = 13263
TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772103(US20250289804, Example 51)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772102(US20250289804, Example 50)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772105(US20250289804, Example 53)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772104(Preparation of 4-((2R,4s,6S)-2-cyano-7-((5-methoxy...)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772107(US20250289804, Example 55)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772106(US20250289804, Example 54)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772109(US20250289804, Example 57)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772108(US20250289804, Example 56)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772111(US20250289804, Example 59)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772110(US20250289804, Example 58)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772113(US20250289804, Example 61)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772115(US20250289804, Example 63)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772114(US20250289804, Example 62)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772087(Preparation of 4-((5S,7S)-2,2-difluoro-8-((5-metho...)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772086(US20250289804, Example 34)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772088(US20250289804, Example 36)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772093(US20250289804, Example 41)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772094(US20250289804, Example 42)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772097(US20250289804, Example 45)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772096(US20250289804, Example 44)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772099(US20250289804, Example 47)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772098(US20250289804, Example 46)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772101(US20250289804, Example 49)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772100(US20250289804, Example 48)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772071(US20250289804, Example 18)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772135(US20250289804, Example 83)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772137(US20250289804, Example 85)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772072(US20250289804, Example 19)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772075(US20250289804, Example 22)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772078(US20250289804, Example 25)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772080(Preparation of 4-((2S,4S)-4-(difluoromethoxy)-1-((...)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772083(US20250289804, Example 31)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772082(US20250289804, Example 30)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772084(US20250289804, Example 32)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772120(US20250289804, Example 68)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772059(US20250289804, Example 4)
Affinity DataIC50: 100nMAssay Description:Compounds disclosed herein were evaluated for their potency to inhibit human C3bBb in a biochemical assay. To generate active C3bBb complex in vitro,...More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772123(US20250289804, Example 71)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772061(US20250289804, Example 8)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772125(US20250289804, Example 73)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772060(US20250289804, Example 7)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772126(US20250289804, Example 74)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772129(US20250289804, Example 77)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772128(US20250289804, Example 76)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772133(US20250289804, Example 81)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772068(US20250289804, Example 15)
Affinity DataIC50: 100nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772070(US20250289804, Example 17)
Affinity DataIC50: 150nMAssay Description:Compounds disclosed herein were evaluated for their potency to inhibit human C3bBb in a biochemical assay. To generate active C3bBb complex in vitro,...More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772134(US20250289804, Example 82)
Affinity DataIC50: 150nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772058(US20250289804, Example 3)
Affinity DataIC50: 150nMAssay Description:Compounds disclosed herein were evaluated for their potency to inhibit human C3bBb in a biochemical assay. To generate active C3bBb complex in vitro,...More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772077(US20250289804, Example 24)
Affinity DataIC50: 150nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

TargetComplement receptor type 1/B/D(Human)
Novartis Pharma

US Patent
LigandPNGBDBM772127(US20250289804, Example 75)
Affinity DataIC50: 150nMAssay Description:Reaction mixture containing 1 nM C3bBb complex.More data for this Ligand-Target Pair
Target InfoPDB
GoogleScholar
Ligand Info
In Depth
Date in BDB:
1/3/2026
Entry Details
US Patent

Displayed 1 to 50 (of 82 total ) | Next | Last >>
Jump to: